Novotech Launches New SMO Business in South Korea
19 July 2017, Sydney, Australia and Seoul, Korea - Asia Pacific CRO Novotech announced it has expanded its business offering to include clinical trial site management organization (SMO) services with the launch of Novotech SMO Korea Co. Limited in South Korea.
Novotech’s new business will train and provide clinical research coordinators (CRCs); as well as site management associates (SMAs) who will be able to support clinical trial principal investigators with site feasibility, patient recruitment and IRB support, based on Novotech’s SMO experience.
Site management organization (SMO) collaboration between principal investigators and sponsors is common within the US, EU, and Japan. Novotech launched its new SMO business in response to unmet industry need in South Korea. South Korea’s SMO industry is still quite young, with the legal foundations of the business model only being established through a revision in its Good Clinical Practice Guidelines in October 2016. Novotech also has several years of experience undertaking SMO projects in Taiwan.
Commenting on the new SMO offering Novotech CEO Dr. John Moller said, “South Korea is without a doubt a global leader within the clinical trials industry and we look forward to providing high quality SMO services to meet growing demand from South Korea.”
“With the launch of our new SMO business, Novotech is committed to providing our clients with high quality clinical trial support across all levels, from start to finish. As the demand for education and quality assurance for clinical trial staff grows, Novotech is not only able to offer clinical service as a CRO; we are now also able to provide a comprehensive range of specialized CRC and SMA services. Through our SMO operations, we will provide a strong supply of CRC and SMA personnel to fulfil South Korea’s industry needs,” said Novotech Executive Director for Asia Operations Dr. Yooni Kim.
For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0
Corporate and media enquiries
Marketing & Communications Manager Justine Lamond
Ph: +61 2 8569 1458
Email: communications@novotech-cro.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
